Alcohol Treatment Guidelines
The Guidelines for the Treatment of Alcohol Problems have been periodically developed over the past 25 years. The present version of the Guidelines was commissioned by the Commonwealth of Australia to remain current and integrated with the updated National Health and Medical Research Council (NHMRC) consumption guidelines (2020). Guidelines are available to download here.
The Australian Government has announced a no-cost education package and training grants for GPs to improve support and increase resources available to GPs to treat drug and alcohol use. Funding has been provided to both Royal Australian College of General Practitioners (RACGP) and the Australian College of Rural and Remote Medicine (ACRRM) to administer the package.
The RACGP has developed it’s Alcohol and Other Drugs (AOD) GP Education Program to provide members with no-cost education to assist and increase capacity to address the AOD needs of their communities. Applications are now open via the RACGP website.
Training assists GPs to upskill in a range of areas, starting with having a conversation with a patient about their AOD use. It also includes current best practice treatment such as pharmacotherapy, withdrawal management and harm minimisation approaches.
The AOD GP Education Program has three entry pathways:
For more information, visit the RACGP Website here or download the
which provides information on the training available in 2022.
Phone: 1800 472 247
The ACRRM Drug and Alcohol Addiction Education Program includes a suite of incentivised activities to strengthen the capacity of General Practitioners to address drug and alcohol addiction in their communities. These training activities include a virtual workshop, an online learning course and webinars with subject matter experts, supported by resources for General Practitioners to use in their practice.
Each activity attracts individual incentive payments for eligible ACRRM members, and can be done separately; however, it is strongly recommended that you to complete the full suite of activities.
Visit the ACRRM website for more information about the DAAE program and register for a training activity now
Opioid Treatment Accreditation Course (OTAC)
The University of Sydney provides free courses to train health professionals on behalf of the NSW Ministry of Health. The courses assist in the development of knowledge, skills, and practices to support the safe prescribing of opioid pharmacotherapies for the treatment of opioid dependence.
Medical and nurse practitioners can complete the Opioid Treatment Accreditation Course (OTAC), which forms part of the process to apply to recieve accreditation as an opioid pharmacotherapy prescriber.
There are 4 courses that are available to complete. Two of these courses (the Fundamentals of Opioid Treatment and OTAC) are related to the accreditation process; the other two are standalone topics relevant to prescribing opioid treatment.
For anyone seeking to complete any of the 4 courses, visit www.otac.org.au to register for an account. For medical and nurse practitioners, there are 3 steps to complete apply for OTP accreditation in NSW:
Have an enquiry? You can send an email to firstname.lastname@example.org or visit the website www.otac.org.au
Treatment of opioid dependency with Depot Buprenorphine
Interim guidelines for depot buprenorphine were developed to provide a framework for clinical decision making for clinicians and consumers in a range of service settings involved in the delivery of treatment of long acting depot buprenorphine products.
Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence
Guidelines should be read in conjunction with the NSW Health Guidelines: Treatment of Opioid Dependence
This webinar aims to explain the clinical guidance, evidence base, pharmacology, and risks associated with depot buprenorphine, and how to implement it as an Opioid Agonist Treatment for opioid dependency. The webinar is presented by Assoc Professor Nicholas Lintzeris, Clinical Director of South Eastern Sydney Local Health District on 16 June 2020
Webinar – Introduction to depot buprenorphine in the treatment of opioid dependent patients
Long acting depot buprenorphine was listed on the Pharmaceutical Benefits Scheme (PBS) on the 1st September 2019 as an s100 drug, making it free to people with an opioid dependency. This webinar explains the clinical guidance, evidence base, pharmacology, and risks associated with depot buprenorphine, and how to implement it as an Opioid Agonist Treatment (OAT) for opioid dependency.
Webinar – Prescribing depot buprenorphine in primary care
From 3 April 2020, Buvidal® – one of the two depot buprenorphine formulations available for the treatment of opioid dependency – will be able to be prescribed in the primary care setting.
This webinar will help GPs identify patients suitable for depot buprenorphine, implement depot buprenorphine as an OAT for opioid dependency, specifically in relation to prescribing, induction, dose alterations & reduction off the drug, incorporate treatment with depot buprenorphine into your practice and comply with regulatory requirements of prescribing and storing of depot buprenorphine.
Webinar – Using Opioid Agonist Treatment for Pharmaceautical Opioid Dependence
Alcohol and Other Drugs Medicare Benefits Schedule (MBS)
In order to ensure that patients receive the necessary care, GPs may consider optimising MBS items to better support their patients with alcohol and other drugs of addiction.
For more information on common MBS items used for the treatment of drug and alcohol for patients, the following resource has been developed:
Telephone and Video Consultations Manual
The University of Adelaide has developed thie manual to support health professionals identify and respond to substance use.